“…Specifically, the TC1 marker genes FCER2 (CD23) and TCL1A are known to be highly expressed in mature naive B cells (Figure 4A; Table S4) (Horns et al, 2020), consistent with an enrichment in TC1 of IgD + and IgM + B cells (36% and 63% of cells, respectively) (Figure S4E) with low levels of inferred somatic mutations (Figure S4F) and minimal clonal expansion (Figures S4G and S4H). In TC3 and TC4, CD27 and CD80, both expressed in MBCs (Moroney et al, 2020;Zuccarino-Catania et al, 2014), were highly expressed (Figure S5A), and the majority of cells in these clusters were IgG1 + (53% and 73% of cells, respectively) (Figure S4E), somatically mutated (Figure S4F) and more clonally expanded than cells in TC1 (Figures S4G and S4H). Cells in TC3 and TC4 also highly expressed CXCR3, a chemokine receptor found on some class switched B cells that is believed to facilitate migration to sites of inflammation (Moroney et al, 2020;Muehlinghaus et al, 2005) and CD70, which is upregulated on stimulated B cells where its interaction with CD27 on effector T cells plays an important role in antiviral T cell responses (Izawa et al, 2017;van Gisbergen et al, 2011) (Figures 4A and S5A).…”